Are you Dr. Holdridge?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 45 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1505 Wigwam Pkwy
Ste 130
Henderson, NV 89074Phone+1 702-856-1400Fax+1 702-856-1407
Summary
- Dr. Regan Holdridge, MD is an oncologist in Henderson, Nevada. She is currently licensed to practice medicine in Nevada and Vermont. She is affiliated with Spring Valley Hospital Medical Center and Southern Hills Hospital and Medical Center.
Education & Training
- University of Vermont Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
- University of Vermont Medical CenterResidency, Internal Medicine, 2002 - 2005
- University of Vermont College of MedicineClass of 2002
Certifications & Licensure
- NV State Medical License 2008 - 2025
- VT State Medical License 2002 - 2008
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20
- Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Publications & Presentations
PubMed
- 59 citationsDiagnosis of second breast cancer events after initial diagnosis of early stage breast cancerDiana S. M. Buist, Linn Abraham, William E. Barlow, Arun Krishnaraj, Regan C. Holdridge
Breast Cancer Research and Treatment. 2010-08-11 - 54 citationsThe Novel Oral Typhoid Vaccine M01ZH09 Is Well Tolerated and Highly Immunogenic in 2 Vaccine PresentationsBeth D. Kirkpatrick, Katherine M. Tenney, Catherine J. Larsson, J. Patrick O'Neill, Cassandra H. Ventrone
The Journal of Infectious Diseases. 2005-08-01 - 7 citationsModified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomize...Heinz-Josef Lenz, Aparna Parikh, David R Spigel, Allen L Cohn, Takayuki Yoshino
Journal for Immunotherapy of Cancer. 2024-03-13